These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 16550531

  • 41. Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment.
    Lê PQ, Gulbis B, Dedeken L, Dupont S, Vanderfaeillie A, Heijmans C, Huybrechts S, Devalck C, Efira A, Dresse MF, Rozen L, Benghiat FS, Ferster A.
    Pediatr Blood Cancer; 2015 Nov; 62(11):1956-61. PubMed ID: 26173735
    [Abstract] [Full Text] [Related]

  • 42. Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response.
    Sadaf A, Quinn CT, Korpik JB, Pfeiffer A, Reynaud M, Niss O, Malik P, Ware RE, Kalfa TA, McGann PT.
    Blood Cells Mol Dis; 2021 Sep; 90():102576. PubMed ID: 34020272
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Use of hydroxyurea in prevention of stroke in children with sickle cell disease.
    Lefèvre N, Dufour D, Gulbis B, Lê PQ, Heijmans C, Ferster A.
    Blood; 2008 Jan 15; 111(2):963-4; author reply 964. PubMed ID: 18182580
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort.
    Quarmyne MO, Dong W, Theodore R, Anand S, Barry V, Adisa O, Buchanan ID, Bost J, Brown RC, Joiner CH, Lane PA.
    Am J Hematol; 2017 Jan 15; 92(1):77-81. PubMed ID: 27761932
    [Abstract] [Full Text] [Related]

  • 47. Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea.
    Khayat AS, Antunes LM, Guimarães AC, Bahia MO, Lemos JA, Cabral IR, Lima PD, Amorim MI, Cardoso PC, Smith MA, Santos RA, Burbano RR.
    Clin Exp Med; 2006 Mar 15; 6(1):33-7. PubMed ID: 16550342
    [Abstract] [Full Text] [Related]

  • 48. DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea.
    Friedrisch JR, Prá D, Maluf SW, Bittar CM, Mergener M, Pollo T, Kayser M, da Silva MA, Henriques JA, da Rocha Silla LM.
    Mutat Res; 2008 Jan 08; 649(1-2):213-20. PubMed ID: 17988936
    [Abstract] [Full Text] [Related]

  • 49. Challenge of managing sickle cell disease in a pediatric population living in kinshasa, democratic republic of congo: a sickle cell center experience.
    Aloni MN, Nkee L.
    Hemoglobin; 2014 Jan 08; 38(3):196-200. PubMed ID: 24669956
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
    Dong M, Mizuno T, Vinks AA.
    Blood Cells Mol Dis; 2017 Sep 08; 67():143-147. PubMed ID: 28807656
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
    Vicari P, Barretto de Mello A, Figueiredo MS.
    Am J Hematol; 2005 Mar 08; 78(3):243-4. PubMed ID: 15726590
    [Abstract] [Full Text] [Related]

  • 54. Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.
    Estepp JH, Wiczling P, Moen J, Kang G, Mack JM, Liem R, Panepinto JA, Garg U, Kearns G, Neville KA.
    Br J Clin Pharmacol; 2018 Jul 08; 84(7):1478-1485. PubMed ID: 28884840
    [Abstract] [Full Text] [Related]

  • 55. Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
    Abdullahi SU, DeBaun MR, Jordan LC, Rodeghier M, Galadanci NA.
    Pediatr Neurol; 2019 Jun 08; 95():73-78. PubMed ID: 30952488
    [Abstract] [Full Text] [Related]

  • 56. Mortality in sickle cell patients on hydroxyurea therapy.
    Bakanay SM, Dainer E, Clair B, Adekile A, Daitch L, Wells L, Holley L, Smith D, Kutlar A.
    Blood; 2005 Jan 15; 105(2):545-7. PubMed ID: 15454485
    [Abstract] [Full Text] [Related]

  • 57. Hydroxyurea Use After Transitions of Care Among Young Adults With Sickle Cell Disease and Tennessee Medicaid Insurance.
    Mathias JG, Nolan VG, Klesges LM, Badawy SM, Cooper WO, Hankins JS, Smeltzer MP.
    JAMA Netw Open; 2021 Oct 01; 4(10):e2128971. PubMed ID: 34643722
    [Abstract] [Full Text] [Related]

  • 58. Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial.
    Galadanci NA, Abdullahi SU, Tabari MA, Abubakar S, Belonwu R, Salihu A, Neville K, Kirkham F, Inusa B, Shyr Y, Phillips S, Kassim AA, Jordan LC, Aliyu MH, Covert BV, DeBaun MR.
    Pediatr Blood Cancer; 2015 Mar 01; 62(3):395-401. PubMed ID: 25399822
    [Abstract] [Full Text] [Related]

  • 59. Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia.
    Power-Hays A, Dong M, Punt N, Mizuno T, Smart LR, Vinks AA, Ware RE.
    Clin Pharmacol Ther; 2024 Sep 01; 116(3):670-677. PubMed ID: 38018175
    [Abstract] [Full Text] [Related]

  • 60. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea.
    Lanzkron S, Haywood C, Segal JB, Dover GJ.
    Am J Hematol; 2006 Dec 01; 81(12):927-32. PubMed ID: 16924648
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.